CompletedPhase 1/2

Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome

Iran218 participantsStarted 2009-10

Plain-language summary

This study is a prospective randomized clinical controlled trial to assess the efficacy of the Methylprednisolone for preventing ovarian hyper stimulation syndrome in in vitro fertilization (IVF) cycles.

Who can participate

Age range18 Years – 35 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Poly Cystic Ovarian Syndrome patients * Indication for IVF/ICSI and Long Protocol ovarian stimulation * Basal FSH≥10 * Normal BMI (20-25) * physical health Exclusion Criteria: * Allergy to GnRH analogues, FSH and corticosteroids * presence of heart failure, recent myocardial infarction * Hypertension * Diabetes mellitus * epilepsy * glaucoma * hypothyroidism * hepatic failure * osteoporosis * peptic ulceration * renal impairment * Using drugs that have interaction with corticosteroids such

What they're measuring

Occurrence rate of Ovarian hyper stimulation syndrome

Timeframe: Until 20 days after embryos transfer

Trial details

NCT IDNCT01014104

SponsorRoyan Institute

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2010-08

View on ClinicalTrials.gov More Ovarian Hyperstimulation Syndrome trials